Search

Your search keyword '"Kooijmans, Sander"' showing total 160 results
Start Over Author "Kooijmans, Sander" Publication Year Range Last 50 years
160 results on '"Kooijmans, Sander"'

1. A modular strategy for extracellular vesicle-mediated CRISPR-Cas9 delivery through aptamer-based loading and UV-activated cargo release

Author

Elsharkasy, Omnia M., primary, Hegeman, Charlotte V., additional, Lansweers, Ivana, additional, Cotugno, Olaf L., additional, de Groot, Ingmar Y., additional, de Wit, Zoe E.N.M.J., additional, Liang, Xiuming, additional, Garcia-Guerra, Antonio, additional, Moorman, Niels J.A., additional, Lefferts, Julliet, additional, de Voogt, Willemijn S., additional, Gitz-Francois, Jerney J., additional, van Wesel, Annet C.W., additional, El Andaloussi, Samir, additional, Schiffelers, Raymond M., additional, Kooijmans, Sander A.A., additional, Mastrobattista, Enrico, additional, Vader, Pieter, additional, and de Jong, Olivier G., additional

Published
2024
Full Text
View/download PDF

5. EV-Elute: a universal platform for enrichment of functional surface marker-defined extracellular vesicle subpopulations

Author

de Voogt, Willemijn S, primary, Frunt, Rowan, additional, Leandro, Raul M, additional, Triesscheijn, Casper S, additional, Monica, Bella, additional, Paspali, Ioanna, additional, Tielemans, Mark, additional, Francois, Jerney JJM, additional, Seinen, Cor W, additional, de Jong, Olivier G, additional, and Kooijmans, Sander AA, additional

Published
2023
Full Text
View/download PDF

8. Increased Bone Marrow Uptake and Accumulation of Very-Late Antigen-4 Targeted Lipid Nanoparticles

Author

Swart, Laura E., primary, Fens, Marcel H. A. M., additional, Oort, Anita van, additional, Waranecki, Piotr, additional, Casimiro, L. Daniel Mata, additional, Tuk, David, additional, Hendriksen, Martijn, additional, Brink, Luca van den, additional, Schweighart, Elizabeth, additional, Seinen, Cor, additional, Nelson, Ryan, additional, Krippner-Heidenreich, Anja, additional, O’Toole, Tom, additional, Schiffelers, Raymond M., additional, Kooijmans, Sander, additional, and Heidenreich, Olaf, additional

Published
2023
Full Text
View/download PDF

10. EV-Elute: a universal platform for enrichment of functional surface marker-defined extracellular vesicle subpopulations

Author

Afd Pharmaceutics, Pharmaceutics, Voogt, Willemijn S de, Frunt, Rowan, Leandro, Raul M, Triesscheijn, Casper S, Monica, Bella, Paspali, Ioanna, Tielemans, Mark, Francois, Jerney JJM, Seinen, Cor W, de Jong, Olivier G., Kooijmans, Sander AA, Afd Pharmaceutics, Pharmaceutics, Voogt, Willemijn S de, Frunt, Rowan, Leandro, Raul M, Triesscheijn, Casper S, Monica, Bella, Paspali, Ioanna, Tielemans, Mark, Francois, Jerney JJM, Seinen, Cor W, de Jong, Olivier G., and Kooijmans, Sander AA

Published
2023

11. Increased Bone Marrow Uptake and Accumulation of Very-Late Antigen-4 Targeted Lipid Nanoparticles

Author

CDL Nanomedicine, Cancer, CTI CFF, Centraal Diagnostisch Laboratorium, Circulatory Health, Swart, Laura E, Fens, Marcel H A M, van Oort, Anita, Waranecki, Piotr, Mata Casimiro, L Daniel, Tuk, David, Hendriksen, Martijn, van den Brink, Luca, Schweighart, Elizabeth, Seinen, Cor, Nelson, Ryan, Krippner-Heidenreich, Anja, O'Toole, Tom, Schiffelers, Raymond M, Kooijmans, Sander, Heidenreich, Olaf, CDL Nanomedicine, Cancer, CTI CFF, Centraal Diagnostisch Laboratorium, Circulatory Health, Swart, Laura E, Fens, Marcel H A M, van Oort, Anita, Waranecki, Piotr, Mata Casimiro, L Daniel, Tuk, David, Hendriksen, Martijn, van den Brink, Luca, Schweighart, Elizabeth, Seinen, Cor, Nelson, Ryan, Krippner-Heidenreich, Anja, O'Toole, Tom, Schiffelers, Raymond M, Kooijmans, Sander, and Heidenreich, Olaf

Published
2023

12. In-vitro and in-silico evidence for oxidative stress as drivers for RDW

Author

CDL Upod, CDL Rode cel, CDL Nanomedicine, Circulatory Health, Centraal Diagnostisch Laboratorium, CDL Cluster Speciële Diagnostiek, Child Health, CDL Cluster 24/7 centraal laboratorium, Other research (not in main researchprogram), Joosse, Huibert Jan, van Oirschot, Brigitte A., Kooijmans, Sander A.A., Hoefer, Imo E., van Wijk, Richard A.H., Huisman, Albert, van Solinge, Wouter W., Haitjema, Saskia, CDL Upod, CDL Rode cel, CDL Nanomedicine, Circulatory Health, Centraal Diagnostisch Laboratorium, CDL Cluster Speciële Diagnostiek, Child Health, CDL Cluster 24/7 centraal laboratorium, Other research (not in main researchprogram), Joosse, Huibert Jan, van Oirschot, Brigitte A., Kooijmans, Sander A.A., Hoefer, Imo E., van Wijk, Richard A.H., Huisman, Albert, van Solinge, Wouter W., and Haitjema, Saskia

Published
2023

13. EV-Elute: a universal platform for enrichment of functional surface marker-defined extracellular vesicle subpopulations

Author

CDL Nanomedicine, Circulatory Health, CDL extracellular vesicles, CDL Contact activatie, Zorgeenheid Vaatchirurgie Medisch, CDL Research analisten, de Voogt, Willemijn, Frunt, Rowan, Leandro, Raul, Triesscheijn, Casper, Monica, Bella, Paspali, Ioanna, Tielemans, Mark, Gitz-Francois, Jerney J. J. M., Seinen, CW, de Jong, Olivier, Kooijmans, Sander, CDL Nanomedicine, Circulatory Health, CDL extracellular vesicles, CDL Contact activatie, Zorgeenheid Vaatchirurgie Medisch, CDL Research analisten, de Voogt, Willemijn, Frunt, Rowan, Leandro, Raul, Triesscheijn, Casper, Monica, Bella, Paspali, Ioanna, Tielemans, Mark, Gitz-Francois, Jerney J. J. M., Seinen, CW, de Jong, Olivier, and Kooijmans, Sander

Published
2023

16. mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells

Author

Bevers, Sanne, Kooijmans, Sander A.A., Van de Velde, Elien, Evers, Martijn J.W., Seghers, Sofie, Gitz-Francois, Jerney J.J.M., van Kronenburg, Nicky C.H., Fens, Marcel H.A.M., Mastrobattista, Enrico, Hassler, Lucie, Sork, Helena, Lehto, Taavi, Ahmed, Kariem E., El Andaloussi, Samir, Fiedler, Katja, Breckpot, Karine, Maes, Michael, Van Hoorick, Diane, Bastogne, Thierry, Schiffelers, Raymond M., De Koker, Stefaan, Afd Pharmaceutics, Pharmaceutics, Laboratory of Molecullar and Cellular Therapy, Basic (bio-) Medical Sciences, Faculty of Medicine and Pharmacy, Afd Pharmaceutics, and Pharmaceutics

Subjects
LNP, mRNA, mRNA-LNP vaccines, design-of-experiments methodology, infectious diseases, Cancer Vaccines, Drug Discovery, Genetics, Animals, cancer, Tissue Distribution, RNA, Messenger, Molecular Biology, antitumor, Pharmacology, extrahepatic delivery, SARS-CoV-2, Vaccination, COVID-19, vaccination, lipid-based nanoparticlelipid-based nanoparticle, immunity, oncology, Nanoparticles, Molecular Medicine, Immunization, immunotherapy, Vaccine, Spleen
Abstract

mRNA vaccines have recently proved to be highly effective against SARS-CoV-2. Key to their success is the lipid-based nanoparticle (LNP), which enables efficient mRNA expression and endows the vaccine with adjuvant properties that drive potent antibody responses. Effective cancer vaccines require long-lived, qualitative CD8 T cell responses instead of antibody responses. Systemic vaccination appears to be the most effective route, but necessitates adaptation of LNP composition to deliver mRNA to antigen-presenting cells. Using a design-of-experiments methodology, we tailored mRNA-LNP compositions to achieve high-magnitude tumor-specific CD8 T cell responses within a single round of optimization. Optimized LNP compositions resulted in enhanced mRNA uptake by multiple splenic immune cell populations. Type I interferon and phagocytes were found to be essential for the T cell response. Surprisingly, we also discovered a yet unidentified role of B cells in stimulating the vaccine-elicited CD8 T cell response. Optimized LNPs displayed a similar, spleen-centered biodistribution profile in non-human primates and did not trigger histopathological changes in liver and spleen, warranting their further assessment in clinical studies. Taken together, our study clarifies the relationship between nanoparticle composition and their T cell stimulatory capacity and provides novel insights into the underlying mechanisms of effective mRNA-LNP-based antitumor immunotherapy.

Published
2022

17. Exploring interactions between extracellular vesicles and cells for innovative drug delivery system design

Author

Kooijmans, Sander, de Jong, Olivier G., Schiffelers, Raymond, Afd Pharmaceutics, Pharmaceutics, Afd Pharmaceutics, and Pharmaceutics

Subjects
Biocompatibility, RNA delivery, Pharmaceutical Science, 02 engineering and technology, Exosomes, Extracellular vesicles, Small Molecule Libraries, Synthetic drugs, Extracellular Vesicles, 03 medical and health sciences, Drug Delivery Systems, Extracellular vesicle surface, Humans, Uptake mechanisms, 030304 developmental biology, Drug Carriers, 0303 health sciences, Chemistry, Effector, Protein delivery, Small molecules, 021001 nanoscience & nanotechnology, Small molecule, Microvesicles, Cell biology, Reporter systems, Drug Design, Drug delivery, 0210 nano-technology
Abstract

Extracellular vesicles (EVs) are submicron cell-secreted structures containing proteins, nucleic acids and lipids. EVs can functionally transfer these cargoes from one cell to another to modulate physiological and pathological processes. Due to their presumed biocompatibility and capacity to circumvent canonical delivery barriers encountered by synthetic drug delivery systems, EVs have attracted considerable interest as drug delivery vehicles. However, it is unclear which mechanisms and molecules orchestrate EV-mediated cargo delivery to recipient cells. Here, we review how EV properties have been exploited to improve the efficacy of small molecule drugs. Furthermore, we explore which EV surface molecules could be directly or indirectly involved in EV-mediated cargo transfer to recipient cells and discuss the cellular reporter systems with which such transfer can be studied. Finally, we elaborate on currently identified cellular processes involved in EV cargo delivery. Through these topics, we provide insights in critical effectors in the EV-cell interface which may be exploited in nature-inspired drug delivery strategies.

Published
2021

20. Delivery of modified mRNA to damaged myocardium by systemic administration of lipid nanoparticles

Author

Afd Pharmaceutics, Virologie, Pharmaceutics, Evers, Martijn J.W., Du, Wenjuan, Yang, Qiangbing, Kooijmans, Sander A.A., Vink, Aryan, van Steenbergen, Mies, Vader, Pieter, de Jager, Saskia C.A., Fuchs, Sabine A., Mastrobattista, Enrico, Sluijter, Joost P.G., Lei, Zhiyong, Schiffelers, Raymond, Afd Pharmaceutics, Virologie, Pharmaceutics, Evers, Martijn J.W., Du, Wenjuan, Yang, Qiangbing, Kooijmans, Sander A.A., Vink, Aryan, van Steenbergen, Mies, Vader, Pieter, de Jager, Saskia C.A., Fuchs, Sabine A., Mastrobattista, Enrico, Sluijter, Joost P.G., Lei, Zhiyong, and Schiffelers, Raymond

Published
2022

21. mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells

Author

Afd Pharmaceutics, Pharmaceutics, Bevers, Sanne, Kooijmans, Sander A.A., Van de Velde, Elien, Evers, Martijn J.W., Seghers, Sofie, Gitz-Francois, Jerney J.J.M., van Kronenburg, Nicky C.H., Fens, Marcel H.A.M., Mastrobattista, Enrico, Hassler, Lucie, Sork, Helena, Lehto, Taavi, Ahmed, Kariem E., El Andaloussi, Samir, Fiedler, Katja, Breckpot, Karine, Maes, Michael, Van Hoorick, Diane, Bastogne, Thierry, Schiffelers, Raymond M., De Koker, Stefaan, Afd Pharmaceutics, Pharmaceutics, Bevers, Sanne, Kooijmans, Sander A.A., Van de Velde, Elien, Evers, Martijn J.W., Seghers, Sofie, Gitz-Francois, Jerney J.J.M., van Kronenburg, Nicky C.H., Fens, Marcel H.A.M., Mastrobattista, Enrico, Hassler, Lucie, Sork, Helena, Lehto, Taavi, Ahmed, Kariem E., El Andaloussi, Samir, Fiedler, Katja, Breckpot, Karine, Maes, Michael, Van Hoorick, Diane, Bastogne, Thierry, Schiffelers, Raymond M., and De Koker, Stefaan

Published
2022

22. Delivery of modified mRNA to damaged myocardium by systemic administration of lipid nanoparticles

Author

CDL Nanomedicine, Circulatory Health, CDL Staf Research, Experimentele Afd. Cardiologie 2, Metabole ziekten patientenzorg, Child Health, Regenerative Medicine and Stem Cells, Onderzoek Cardiovasculair Reg. Med., CDL Cluster Onderzoek en Onderwijs, Cancer, Evers, Martijn J W, Du, Wenjuan, Yang, Qiangbing, Kooijmans, Sander A A, Vink, Arjan, van Steenbergen, Mies, Vader, Pieter, de Jager, Saskia C A, Fuchs, Sabine A, Mastrobattista, Enrico, Sluijter, Joost P G, Lei, Zhiyong, Schiffelers, Raymond, CDL Nanomedicine, Circulatory Health, CDL Staf Research, Experimentele Afd. Cardiologie 2, Metabole ziekten patientenzorg, Child Health, Regenerative Medicine and Stem Cells, Onderzoek Cardiovasculair Reg. Med., CDL Cluster Onderzoek en Onderwijs, Cancer, Evers, Martijn J W, Du, Wenjuan, Yang, Qiangbing, Kooijmans, Sander A A, Vink, Arjan, van Steenbergen, Mies, Vader, Pieter, de Jager, Saskia C A, Fuchs, Sabine A, Mastrobattista, Enrico, Sluijter, Joost P G, Lei, Zhiyong, and Schiffelers, Raymond

Published
2022

24. Rationally designed mRNA-loaded lipid nanoparticles provoke strong antitumor T cell immunity which critically depends on specific immune cell subsets

Author

Kooijmans, Sander, Bevers, Sanne, Van De Velde, Elien, Evers, Martijn, Seghers, Sofie, Gitz-François, Jerney, Hassler, Lucie, Breckpot, Karine, Bastogne, Thierry, Schiffelers, Raymond, De Koker, Stefaan, CDL Research, University Medical Center Utrecht, Utrecht, Netherlands, eTheRNA Immunotherapies, Niel, Belgium, Laboratory for Molecular and Cellular Therapy, Vrije Universiteit Brussel, Brussels, BelgiumLaboratory for Molecular and Cellular Therapy, CYBERnano [Villers-lès-Nancy], Laboratory for Molecular and Cellular Therapy, Vrije Universiteit Brussel, Brussels, Belgium, Centre de Recherche en Automatique de Nancy (CRAN), Centre National de la Recherche Scientifique (CNRS)-Université de Lorraine (UL), Biology, genetics and statistics (BIGS), Inria Nancy - Grand Est, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Institut Élie Cartan de Lorraine (IECL), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), University Medical Center [Utrecht], eTheRNA Immunotherapies NV, Vrije Universiteit Brussel [Bruxelles] (VUB), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), and Bastogne, Thierry

Subjects
Vaccine (or Immunomodulatory), [STAT.AP]Statistics [stat]/Applications [stat.AP], [SDV.BIO]Life Sciences [q-bio]/Biotechnology, [STAT.AP] Statistics [stat]/Applications [stat.AP], [SDV.CAN] Life Sciences [q-bio]/Cancer, Nanoparticle/nanomaterial, [SPI.NANO] Engineering Sciences [physics]/Micro and nanotechnologies/Microelectronics, Formulation development, [SDV.CAN]Life Sciences [q-bio]/Cancer, DNA/RNA, [SPI.NANO]Engineering Sciences [physics]/Micro and nanotechnologies/Microelectronics, ComputingMilieux_MISCELLANEOUS, [SDV.BIO] Life Sciences [q-bio]/Biotechnology
Abstract

International audience

Published
2021

25. Tuning LNPs to target antigen presenting cells in spleen induces CD8 T-cell responses and tumor regression in mice

Author

Bevers, Sanne, Kooijmans, Sander, van de Velde, Elien, Evers, Martijn, Seghers, Sofie, Gitz-François, Jerney, Hassler, Lucie, Breckpot, Karine, Bastogne, Thierry, Schiffelers, Raymond, De Koker, Stefaan, eTheRNA Immunotherapies NV, Vrije Universiteit Brussel (VUB), University Medical Center [Utrecht], CYBERnano [Villers-lès-Nancy], Centre de Recherche en Automatique de Nancy (CRAN), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Biology, genetics and statistics (BIGS), Inria Nancy - Grand Est, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Institut Élie Cartan de Lorraine (IECL), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), CIMT Association for Cancer Immunotherapy, Laboratory of Molecular and Cellular Therapy, Vrije Universiteit Brussel, Brussels, Belgium, eTheRNA Immunotherapies, Niel, Belgium, CDL Research, University Medical Center Utrecht, Utrecht, Netherlands, Bastogne, Thierry, and Centre National de la Recherche Scientifique (CNRS)-Université de Lorraine (UL)

Subjects
[STAT.AP]Statistics [stat]/Applications [stat.AP], [SDV.BIO]Life Sciences [q-bio]/Biotechnology, [SDV.CAN] Life Sciences [q-bio]/Cancer, [STAT.AP] Statistics [stat]/Applications [stat.AP], [SPI.NANO] Engineering Sciences [physics]/Micro and nanotechnologies/Microelectronics, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SPI.NANO]Engineering Sciences [physics]/Micro and nanotechnologies/Microelectronics, [SDV.BIO] Life Sciences [q-bio]/Biotechnology
Abstract

International audience; Intravenous (i‧v.) delivery of vaccines is emerging as an appealing approach to evoke high-quality T-cell responses needed to combat tumors. Messenger RNA (mRNA) holds huge potential to use in vaccination because of its ease of production, intrinsic adjuvant activity and the high versatility in antigen design, but also requires a potent delivery vehicle to enable antigen expression and immune activation. Lipid based nanoparticles (LNP) are currently the clinically most advanced tool to protect mRNA from degradation and efficiently deliver it inside cells. Yet, i‧v administered LNPs generally tend to distribute to the liver. We hypothesized LNPs can be altered to target antigen presenting cells in the spleen and hereby orchestrate specific and durable immune responses against cancer antigens. By using a design of experiment methodology we were able to screen LNPs in a cost and time effective manner. LNP compositions that were evaluated solely differed in the molar ratios of ionizable lipid, phospholipid, cholesterol and PEG-lipid and the choice of the PEG-lipid. Bayesian Regression modeling enabled us to identify LNP compositions conferring maximum immunogenicity upon i‧v. administration. To link LNP compositions to T cell responses and biodistribution, we prepared the same LNPs packaging either the viral oncoprotein E7 as an antigen or Cy-5 labelled luciferase mRNA. The optimized LNP compositions showed increased localization in the spleen (of mice and non-human primates) and uptake by antigen presenting cells. Furthermore, they induced high magnitude CD8 T cell responses that conferred strong antitumor immunity and prolonged survival of TC-1 tumor bearing mice. Mechanistically, type I interferons and phagocytes were found to be essential for eliciting strong T-cell responses. Unexpectedly, we identified B cells as major mediators of the vaccine- elicited T-cell response, revealing a previously undocumented role of these cells in the immune response to mRNA LNPs. Our data highlight the potential of optimizing LNP compositions by tailoring of the molar ratio of the lipids compromising the LNPs and provide insight in the cell types involved in the mRNA LNP-induced immune response. Collectively, our results illustrate the great promise of intravenous mRNA LNP vaccination for the treatment of cancer.

Published
2021

26. A post-insertion strategy for surface functionalization of bacterial and mammalian cell-derived extracellular vesicles

Author

Jiang, Linglei, Luirink, Joen, Kooijmans, Sander A A, van Kessel, Kok P M, Jong, Wouter, van Essen, Max, Seinen, Cor W, de Maat, Steven, de Jong, Olivier G, Gitz-François, Jerney F F, Hennink, Wim E, Vader, Pieter, Schiffelers, Raymond M, Pharmaceutics, Afd Pharmaceutics, Molecular Microbiology, AIMMS, LaserLaB - Molecular Biophysics, Pharmaceutics, and Afd Pharmaceutics

Subjects
Surface Properties, Blotting, Western, Biophysics, Cell Culture Techniques, Outer membrane vesicles, 02 engineering and technology, Extracellular vesicles, Biochemistry, Post insertion, 03 medical and health sciences, Mice, Microscopy, Electron, Transmission, Labelling, Cell Line, Tumor, Animals, Humans, Molecular Biology, 030304 developmental biology, 0303 health sciences, Liposome, Bacteria, Chemistry, Translation (biology), 021001 nanoscience & nanotechnology, Flow Cytometry, Poly(ethylene glycol)lipids, Immunohistochemistry, Cell biology, Bacterial Outer Membrane, HEK293 Cells, Post-insertion, Nucleic acid, Surface modification, Electrophoresis, Polyacrylamide Gel, 0210 nano-technology, Drug carrier
Abstract

Extracellular vesicles (EVs) are nanoparticles which are released by cells from all three domains of life: Archaea, Bacteria and Eukarya. They can mediate cell-cell communication by transferring cargoes such as proteins and nucleic acids between cells. EVs receive great interest in both academia and industry as they have the potential to be natural drug carriers or vaccine candidates. However, limitations to their clinical translation exist as efficient isolation, loading, labelling and surface-engineering methods are lacking. In this article, we investigate a ‘post-insertion’ approach, which is commonly used in the functionalization of liposomes in the pharmaceutical field, on two different EV types: mammalian cell-derived EVs and bacteria-derived EVs. We aimed to find an easy and flexible approach to functionalize EVs, thereby improving the labelling, isolation, and surface-engineering.

Published
2021

27. easyQBD: A quality by design SaaS platform. Application to the development of lipid nanoparticles for mRNA delivery

Author

Bastogne, Thierry, Bevers, Sanne, Kooijmans, Sander, Hassler, Lucie, Andaloussi, Samir El, Schiffelers, Raymond, de Koker, Stefaan, Bastogne, Thierry, Centre de Recherche en Automatique de Nancy (CRAN), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Biology, genetics and statistics (BIGS), Inria Nancy - Grand Est, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Institut Élie Cartan de Lorraine (IECL), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), CYBERnano [Villers-lès-Nancy], eTheRNA Immunotherapies, Niel, Belgium, UMC Utrecht, University Medical Center [Utrecht], Karolinska Institutet [Stockholm], Centre National de la Recherche Scientifique (CNRS)-Université de Lorraine (UL), eTheRNA Immunotherapies NV, and Utrecht Brain Center [UMC]

Subjects
[STAT.AP]Statistics [stat]/Applications [stat.AP], [STAT.AP] Statistics [stat]/Applications [stat.AP], [SDV.CAN] Life Sciences [q-bio]/Cancer, [SPI.NANO] Engineering Sciences [physics]/Micro and nanotechnologies/Microelectronics, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SPI.NANO]Engineering Sciences [physics]/Micro and nanotechnologies/Microelectronics, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2021

29. A post-insertion strategy for surface functionalization of bacterial and mammalian cell-derived extracellular vesicles

Author

Pharmaceutics, Afd Pharmaceutics, Jiang, Linglei, Luirink, Joen, Kooijmans, Sander A A, van Kessel, Kok P M, Jong, Wouter, van Essen, Max, Seinen, Cor W, de Maat, Steven, de Jong, Olivier G, Gitz-François, Jerney F F, Hennink, Wim E, Vader, Pieter, Schiffelers, Raymond M, Pharmaceutics, Afd Pharmaceutics, Jiang, Linglei, Luirink, Joen, Kooijmans, Sander A A, van Kessel, Kok P M, Jong, Wouter, van Essen, Max, Seinen, Cor W, de Maat, Steven, de Jong, Olivier G, Gitz-François, Jerney F F, Hennink, Wim E, Vader, Pieter, and Schiffelers, Raymond M

Published
2021

31. A post-insertion strategy for surface functionalization of bacterial and mammalian cell-derived extracellular vesicles

Author

CDL Nanomedicine, Circulatory Health, MMB Research line 1, Infection & Immunity, CDL Research analisten, ZL Algemene en Acute Nec Medisch, Centraal Diagnostisch Laboratorium, CDL Contact activatie, CDL Cluster Onderzoek en Onderwijs, Cancer, Jiang, Linglei, Luirink, Joen, Kooijmans, Sander A A, van Kessel, Kok P M, Jong, Wouter, van Essen, Max, Seinen, Cor W, de Maat, Steven, de Jong, Olivier G, Gitz-François, Jerney F F, Hennink, Wim E, Vader, Pieter, Schiffelers, Raymond M, CDL Nanomedicine, Circulatory Health, MMB Research line 1, Infection & Immunity, CDL Research analisten, ZL Algemene en Acute Nec Medisch, Centraal Diagnostisch Laboratorium, CDL Contact activatie, CDL Cluster Onderzoek en Onderwijs, Cancer, Jiang, Linglei, Luirink, Joen, Kooijmans, Sander A A, van Kessel, Kok P M, Jong, Wouter, van Essen, Max, Seinen, Cor W, de Maat, Steven, de Jong, Olivier G, Gitz-François, Jerney F F, Hennink, Wim E, Vader, Pieter, and Schiffelers, Raymond M

Published
2021

33. Recombinant phosphatidylserine-binding nanobodies for targeting of extracellular vesicles to tumor cells: a plug-and-play approach† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c7nr06966a

Author

Kooijmans, Sander A. A., Gitz-Francois, Jerney J. J. M., Schiffelers, Raymond M., and Vader, Pieter

Subjects
ErbB Receptors, Chemistry, Extracellular Vesicles, Drug Delivery Systems, HEK293 Cells, Recombinant Fusion Proteins, Antigens, Surface, Humans, Phosphatidylserines, Single-Domain Antibodies, Milk Proteins
Abstract

Decoration of isolated extracellular vesicles with recombinant phosphatidylserine-binding nanobodies increases their uptake by tumor cells., Extracellular vesicles (EVs) are increasingly being recognized as candidate drug delivery systems due to their ability to functionally transfer biological cargo between cells. However, manipulation of targeting properties of EVs through engineering of the producer cells can be challenging and time-consuming. As a novel approach to confer tumor targeting properties to isolated EVs, we generated recombinant fusion proteins of nanobodies against the epidermal growth factor receptor (EGFR) fused to phosphatidylserine (PS)-binding domains of lactadherin (C1C2). C1C2-nanobody fusion proteins were expressed in HEK293 cells and isolated from culture medium with near-complete purity as determined by SDS-PAGE. Fusion proteins specifically bound PS and showed no affinity for other common EV membrane lipids. Furthermore, C1C2 fused to anti-EGFR nanobodies (EGa1-C1C2) bound EGFR with high affinity and competed with binding of its natural ligand EGF, as opposed to C1C2 fused to non-targeting control nanobodies (R2-C1C2). Both proteins readily self-associated onto membranes of EVs derived from erythrocytes and Neuro2A cells without affecting EV size and integrity. EV-bound R2-C1C2 did not influence EV–cell interactions, whereas EV-bound EGa1-C1C2 dose-dependently enhanced specific binding and uptake of EVs by EGFR-overexpressing tumor cells. In conclusion, we developed a novel strategy to efficiently and universally confer tumor targeting properties to PS-exposing EVs after their isolation, without affecting EV characteristics, circumventing the need to modify EV-secreting cells. This strategy may also be employed to decorate EVs with other moieties, including imaging probes or therapeutic proteins.

Published
2018

34. Interfering with endolysosomal trafficking enhances release of bioactive exosomes

Author

Experimentele Afd. Cardiologie 2, CDL Nanomedicine, Circulatory Health, Onderzoek Cardiovasculair Reg. Med., Regenerative Medicine and Stem Cells, CDL Cluster Onderzoek en Onderwijs, Cancer, Ortega, Francisco G., Roefs, Marieke T., de Miguel Perez, Diego, Kooijmans, Sander A., de Jong, Olivier G., Sluijter, Joost P., Schiffelers, Raymond M., Vader, Pieter, Experimentele Afd. Cardiologie 2, CDL Nanomedicine, Circulatory Health, Onderzoek Cardiovasculair Reg. Med., Regenerative Medicine and Stem Cells, CDL Cluster Onderzoek en Onderwijs, Cancer, Ortega, Francisco G., Roefs, Marieke T., de Miguel Perez, Diego, Kooijmans, Sander A., de Jong, Olivier G., Sluijter, Joost P., Schiffelers, Raymond M., and Vader, Pieter

Published
2019

35. Drug Delivery with Extracellular Vesicles: From Imagination to Innovation

Author

CDL Nanomedicine, Circulatory Health, Experimentele Afd. Cardiologie 1, Onderzoek Cardiovasculair Reg. Med., Regenerative Medicine and Stem Cells, CDL Cluster Onderzoek en Onderwijs, Cancer, De Jong, Olivier G., Kooijmans, Sander A.A., Murphy, Daniel E., Jiang, Linglei, Evers, Martijn J.W., Sluijter, Joost P.G., Vader, Pieter, Schiffelers, Raymond M., CDL Nanomedicine, Circulatory Health, Experimentele Afd. Cardiologie 1, Onderzoek Cardiovasculair Reg. Med., Regenerative Medicine and Stem Cells, CDL Cluster Onderzoek en Onderwijs, Cancer, De Jong, Olivier G., Kooijmans, Sander A.A., Murphy, Daniel E., Jiang, Linglei, Evers, Martijn J.W., Sluijter, Joost P.G., Vader, Pieter, and Schiffelers, Raymond M.

Published
2019

39. The fluid membrane determines mechanics of erythrocyte extracellular vesicles and is softened in hereditary spherocytosis

Author

CDL Patiëntenzorg KC, Circulatory Health, CDL Nanomedicine, SCT patientenzorg, Child Health, Regenerative Medicine and Stem Cells, CDL Cluster Onderzoek en Onderwijs, Vorselen, Daan, van Dommelen, Susan M., Sorkin, Raya, Piontek, Melissa C., Schiller, Jürgen, Döpp, Sander T., Kooijmans, Sander A.A., van Oirschot, Brigitte A., Versluijs, Birgitta A., Bierings, Marc B., van Wijk, Richard, Schiffelers, Raymond M., Wuite, Gijs J.L., Roos, Wouter H., CDL Patiëntenzorg KC, Circulatory Health, CDL Nanomedicine, SCT patientenzorg, Child Health, Regenerative Medicine and Stem Cells, CDL Cluster Onderzoek en Onderwijs, Vorselen, Daan, van Dommelen, Susan M., Sorkin, Raya, Piontek, Melissa C., Schiller, Jürgen, Döpp, Sander T., Kooijmans, Sander A.A., van Oirschot, Brigitte A., Versluijs, Birgitta A., Bierings, Marc B., van Wijk, Richard, Schiffelers, Raymond M., Wuite, Gijs J.L., and Roos, Wouter H.

Published
2018

40. Recombinant phosphatidylserine-binding nanobodies for targeting of extracellular vesicles to tumor cells: a plug-and-play approach

Author

CDL Nanomedicine, Circulatory Health, Centraal Diagnostisch Laboratorium, CDL Staf Research, Kooijmans, Sander A A, Gitz-Francois, Jerney J J M, Schiffelers, Raymond M, Vader, Pieter, CDL Nanomedicine, Circulatory Health, Centraal Diagnostisch Laboratorium, CDL Staf Research, Kooijmans, Sander A A, Gitz-Francois, Jerney J J M, Schiffelers, Raymond M, and Vader, Pieter

Published
2018

41. Dendritic Cell Targeting mRNA Lipopolyplexes Combine Strong Antitumor T-Cell Immunity with Improved Inflammatory Safety

Author

Van der Jeught, Kevin, primary, De Koker, Stefaan, additional, Bialkowski, Lukasz, additional, Heirman, Carlo, additional, Tjok Joe, Patrick, additional, Perche, Federico, additional, Maenhout, Sarah, additional, Bevers, Sanne, additional, Broos, Katrijn, additional, Deswarte, Kim, additional, Malard, Virginie, additional, Hammad, Hamida, additional, Baril, Patrick, additional, Benvegnu, Thierry, additional, Jaffrès, Paul-Alain, additional, Kooijmans, Sander A. A., additional, Schiffelers, Raymond, additional, Lienenklaus, Stefan, additional, Midoux, Patrick, additional, Pichon, Chantal, additional, Breckpot, Karine, additional, and Thielemans, Kris, additional

Published
2018
Full Text
View/download PDF

42. In Situ Gelling Liquid Crystalline System as Local siRNA Delivery System

Author

Borgheti-Cardoso, Livia N., Kooijmans, Sander A.A., Fens, Marcel H.A.M., Van der Meel, Roy, De Carvalho Vicentini, Fabiana Testa Moura, Fantini, Marcia C.A., Bentley, Maria Vitória Lopes Badra, Schiffelers, Raymond M., Borgheti-Cardoso, Livia N., Kooijmans, Sander A.A., Fens, Marcel H.A.M., Van der Meel, Roy, De Carvalho Vicentini, Fabiana Testa Moura, Fantini, Marcia C.A., Bentley, Maria Vitória Lopes Badra, and Schiffelers, Raymond M.

Published
2017

43. In Situ Gelling Liquid Crystalline System as Local siRNA Delivery System

Author

CDL Nanomedicine, Circulatory Health, Cancer, Infection & Immunity, CDL Staf Research, Borgheti-Cardoso, Livia N., Kooijmans, Sander A.A., Fens, Marcel H.A.M., Van der Meel, Roy, De Carvalho Vicentini, Fabiana Testa Moura, Fantini, Marcia C.A., Bentley, Maria Vitória Lopes Badra, Schiffelers, Raymond M., CDL Nanomedicine, Circulatory Health, Cancer, Infection & Immunity, CDL Staf Research, Borgheti-Cardoso, Livia N., Kooijmans, Sander A.A., Fens, Marcel H.A.M., Van der Meel, Roy, De Carvalho Vicentini, Fabiana Testa Moura, Fantini, Marcia C.A., Bentley, Maria Vitória Lopes Badra, and Schiffelers, Raymond M.

Published
2017

47. Liposomal prednisolone inhibits tumor growth in a spontaneous mouse mammary carcinoma model

Author

Sub General Pharmaceutics, Sub Drug targeting, Pharmaceutics, Deshantri, Anil K., Kooijmans, Sander A A, Kuijpers, Sylvia A., Gomes Coimbra, Maria, Hoeppener, Astrid, Storm, G, Fens, Marcel H A M, Schiffelers, Raymond M., Sub General Pharmaceutics, Sub Drug targeting, Pharmaceutics, Deshantri, Anil K., Kooijmans, Sander A A, Kuijpers, Sylvia A., Gomes Coimbra, Maria, Hoeppener, Astrid, Storm, G, Fens, Marcel H A M, and Schiffelers, Raymond M.

Published
2016

48. Liposomal prednisolone inhibits tumor growth in a spontaneous mouse mammary carcinoma model

Author

CDL Nanomedicine, Circulatory Health, Cancer, CDL Staf Research, Deshantri, Anil K., Kooijmans, Sander A A, Kuijpers, Sylvia A., Coimbra, Maria, Hoeppener, Astrid, Storm, Gert, Fens, Marcel H A M, Schiffelers, Raymond M., CDL Nanomedicine, Circulatory Health, Cancer, CDL Staf Research, Deshantri, Anil K., Kooijmans, Sander A A, Kuijpers, Sylvia A., Coimbra, Maria, Hoeppener, Astrid, Storm, Gert, Fens, Marcel H A M, and Schiffelers, Raymond M.

Published
2016

49. Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting

Author

CDL Nanomedicine, Centraal Diagnostisch Laboratorium, Infection & Immunity, Circulatory Health, CDL Staf Research, Kooijmans, Sander A A, Aleza, Clara Gómez, Roffler, Steve R, van Solinge, Wouter W, Vader, Pieter, Schiffelers, Raymond M, CDL Nanomedicine, Centraal Diagnostisch Laboratorium, Infection & Immunity, Circulatory Health, CDL Staf Research, Kooijmans, Sander A A, Aleza, Clara Gómez, Roffler, Steve R, van Solinge, Wouter W, Vader, Pieter, and Schiffelers, Raymond M

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results